Project Grant R01AI182286
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $426,938 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant will fund research to explore combining human monoclonal antibodies targeting the Reticulocyte-binding protein 5 (RH5) with small molecule inhibitors to enhance efficacy and prevent drug resistance against asexual Plasmodium falciparum malaria parasites. The research aims to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $462,000 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the University of Rochester. The grant aims to investigate how the human microbiome differentially primes the immune system, particularly neutrophils, and how this may impact susceptibility and response to sepsis. Preliminary evidence suggests the microbiome mediates "training" of neutrophils in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $891,678 to the Scripps Research Institute in La Jolla, CA to conduct research on how metabolites from the intestinal microbiota can modulate host immune responses. The researchers will employ chemical biology and proteomics methods to identify specific microbiota-associated bile acid protein targets in mammalian cells...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $192,364 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Yale University on August 4, 2025. The project aims to investigate the impact of antimalarial drugs on parasite development and drug resistance selection within mosquito vectors. The research combines controlled lab studies of mosquito and parasite strains, as well as analysis of field samples from Burkina Faso and Senegal,...
- This $244,440 federal Project Grant was awarded on January 14, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant was awarded to the Albert Einstein College of Medicine in Bronx, New York to conduct research on the role of cytolytic ZEB2+ memory CD4+ T cells in providing protection against the liver stage of malaria infection. The research seeks to gain insights into the cellular immune...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $781,241 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Indiana University (Indiana University Indianapolis) to conduct a systems analysis to understand the differential pharmacokinetics and protective efficacy of anti-malarial monoclonal antibodies in field trials. The project aims to leverage clinical data, pharmacokinetic information, and biospecimens from a Phase...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $155,227 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The funding supports research on an unconventional regimen using a biofilm disruptor as an adjunct with antibiotics to treat Mycobacterium abscessus chronic lung disease. The goal is to generate proof-of-concept data on this non-traditional strategy to disrupt M. abscessus biofilms in the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $212,169 federal Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University for the project "ADVANCING MENTORSHIP AT THE JOHNS HOPKINS INTEGRATED CENTER FOR COMBATING ANTIMICROBIAL RESISTANT BACTERIA." The project, awarded on Jan 24, 2025, aims to support the principal investigator's research focused on developing novel approaches to treating...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill (UNC-CH). The purpose of this 2-year grant, with a start date of May 13, 2025, is to develop a novel platform for delivering therapeutic genetic payloads to targeted bacterial species within complex human microbiomes. Specifically, the research aims to engineer...
- This $230,808 project grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by Washington University in St. Louis to investigate heme homeostasis mechanisms in the malaria parasite Plasmodium falciparum. The project aims to identify parasite heme-binding proteins and assess their essentiality for parasite viability, as well as examine the role of the heme...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $636,193 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University on August 25, 2025. The grant supports research to investigate the relationships between the human gut microbiome and malaria infection, severity, and antimalarial drug pharmacokinetics. The project will leverage existing clinical trial samples and data to characterize the gut microbiome using metagenomics and metatranscriptomics, and assess impacts on malaria outcomes and antimalarial drug levels. The research aims to elucidate the interactions between the gut microbiome and malaria pathogenesis, with the ultimate goal of informing new therapeutic approaches. The grant project will run through July 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $636.2k | 8/25/25 |